Industry-Sponsored Research Week

MD Anderson inks research and commercialization agreement with Xencor for cancer research

By David Schwartz
Published: January 12th, 2021

The University of Texas MD Anderson Cancer Center has signed on with biotech company Xencor for a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for potential cancer treatment.

The collaboration joins Xencor’s innovative XmAb technology and protein engineering expertise to create bispecific antibodies with MD Anderson’s expertise in the research and discovery of novel therapeutic antibodies, including the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform, part of MD Anderson’s Therapeutics Discovery division.

“Xencor’s modular antibody engineering platform enables the rapid generation of XmAb bispecific antibodies, and our research collaboration with MD Anderson will further expand the use of our technology to explore novel therapeutic targets, which could result in the creation of new therapies for patients with cancer,” said John Desjarlais, senior vice president and chief scientific officer at Xencor.

“There is an urgent need to discover new therapeutic targets and to develop antibody-based strategies to trigger an immune response against the tumors that express them,” said Dongxing Zha, head of the ORBIT platform at MD Anderson. “Xencor’s multi-format-capable CD3 bispecific antibody platform enables us to rapidly develop and investigate therapies against intriguing tumor targets, and we look forward to evaluating the first candidates to be engineered as part of this collaboration.”

MD Anderson will work to identify and develop potential antibodies, collaborating with Xencor to apply its technology to create therapeutic candidates. MD Anderson will then conduct and fund all preclinical activities to advance candidates toward clinical studies.

As part of the agreement, Xencor gets certain exclusive options to license worldwide rights to develop and commercialize new medicines arising from the research collaboration. For programs not licensed by Xencor, the company will receive a portion of future payments received by MD Anderson.

Source: The Pharma Letter

Posted under: University-Industry Engagement Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment